Ipamorelin vs HGH 191AA
Side-by-Side Comparison
| Attribute | Ipamorelin | Hgh 191aa |
|---|---|---|
| Category | Growth Hormone Secretagogue | Growth Hormone |
| Mechanism | Ipamorelin (sequence: Aib-His-D-2Nal-D-Phe-Lys-NH2) selectively binds to the Growth Hormone Secretagogue Receptor (GHS-R1a) on anterior pituitary somatotroph cells, increasing cAMP and activating... | HGH 191AA binds to the growth hormone receptor (GHR) on target cells, triggering JAK2-STAT5 signaling, which drives transcription of IGF-1 and other growth factors. |
| Evidence Rating | D — Preclinical | A — FDA Approved |
| Clinical Status | Research-only / Not approved for human use | FDA-approved (multiple indications). Numerous brand-name products available worldwide. |
| Safety Profile | Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies; Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours | Common: injection site reactions, fluid retention, joint pain/stiffness, carpal tunnel syndrome; Metabolic: insulin resistance, hyperglycemia (dose-dependent), may precipitate diabetes |
| Route | Subcutaneous | Subcutaneous injection |
| Dose Range | 100–300 mcg per injection, 2–3x daily | 0.15-2 mg per injection (0.5-6 IU) |
| Frequency | 2–3 times daily (typically before meals and before bed) | Once daily |
| Molecular Weight | ~711.9 g/mol | ~22,124 g/mol |
| Half-Life | ~2 hours | ~3-5 hours (SC) |
Overview
Ipamorelin and HGH 191AA are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, dosing protocols, and safety profiles to help researchers understand the key differences and overlaps.
Ipamorelin — Mechanism & Evidence
Ipamorelin is the most selective growth hormone secretagogue (GHS) available, a synthetic pentapeptide (MW ~711.86 g/mol, formula C38H49N9O5) that stimulates pulsatile GH release from the pituitary gland without significantly affecting cortisol, prolactin, or appetite. It is widely regarded as the mildest GHS, making it popular in anti-aging, body composition, and recovery contexts. However, research on ipamorelin is limited, and it is not FDA-approved for any indication.
Key claims: Increases growth hormone levels; Improves body composition; Improves sleep quality.
HGH 191AA — Mechanism & Evidence
HGH 191AA refers to recombinant human growth hormone (somatropin) — a 191-amino acid, single-chain polypeptide (MW ~22,124 g/mol) identical in sequence to endogenous pituitary growth hormone. It is FDA-approved for growth hormone deficiency in children and adults, Turner syndrome, chronic renal insufficiency, Prader-Willi syndrome, and HIV-associated wasting. In the peptide community, "191AA" distinguishes legitimate somatropin from the older 192-amino acid variant (somatrem, which had an extra methionine and higher immunogenicity).
Key claims: Treats growth hormone deficiency; Improves body composition in GH-deficient adults; Anti-aging and rejuvenation effects in healthy elderly.
Shared Research Applications
Both peptides are studied for: Body Composition.
Ipamorelin is also researched for: Anti-Aging, Sleep.
HGH 191AA is also researched for: Anti-Aging & Longevity.
Safety Considerations
Ipamorelin: Widely regarded as the mildest GHS available; minimal side effects in published animal and human studies Common: injection site reactions (redness, swelling, bruising) in 15-30% of users, resolving within 24-48 hours Common: mild temporary "head rush" or flushing immediately after injection due to sudden vasodilation
HGH 191AA: Common: injection site reactions, fluid retention, joint pain/stiffness, carpal tunnel syndrome Metabolic: insulin resistance, hyperglycemia (dose-dependent), may precipitate diabetes Endocrine: gynecomastia, hypothyroidism (may unmask central hypothyroidism)
Related Products
Related Research News
CJC-1295 with DAC and Ipamorelin: Growth Hormone Research Guide
CJC-1295 with DAC and Ipamorelin represent key compounds in growth hormone research, targeting distinct pathways for GH and IGF-1 signaling. CJC-1295 with DAC acts as a long-acting GHRH analogue with a half-life of 5.8 to 8.1 days, while Ipamorelin functions as a selective growth hormone secretagogue via the ghrelin receptor. Together, they support studies on metabolism, recovery, and body composition.
Ipamorelin vs GHRP-2: Which Offers More Targeted GH Release?
Ipamorelin and GHRP-2 both stimulate growth hormone release via the ghrelin receptor, but Ipamorelin provides more selective action with minimal impact on other hormones like ACTH and cortisol. GHRP-2 delivers stronger GH pulses alongside broader endocrine effects. Combining them can enhance overall GH output through additive receptor stimulation.
Ipamorelin: Selective GH Secretagogue for Clean Pulsatile Release
Ipamorelin, a third-generation GHS-R1a agonist (CAS 170851-70-4), stimulates pulsatile growth hormone release without elevating cortisol or prolactin, unlike earlier GHRPs. This selectivity supports precise research into GH axis effects, IGF-1 pathways, body composition, recovery, and sleep. Studies highlight its role in anabolic processes and synergy with CJC-1295 for enhanced GH output.